{"pmid":32404477,"title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","text":["A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.","Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design.","Science","Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei","32404477"],"abstract":["Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. B38 and H4 block the binding between virus S-protein RBD and cellular receptor ACE2. A competition assay indicates their different epitopes on the RBD, making them a potential virus-targeting MAb-pair to avoid immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design."],"journal":"Science","authors":["Wu, Yan","Wang, Feiran","Shen, Chenguang","Peng, Weiyu","Li, Delin","Zhao, Cheng","Li, Zhaohui","Li, Shihua","Bi, Yuhai","Yang, Yang","Gong, Yuhuan","Xiao, Haixia","Fan, Zheng","Tan, Shuguang","Wu, Guizhen","Tan, Wenjie","Lu, Xuancheng","Fan, Changfa","Wang, Qihui","Liu, Yingxia","Zhang, Chen","Qi, Jianxun","Gao, George Fu","Gao, Feng","Liu, Lei"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404477","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1126/science.abc2241","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845583671298,"score":9.490897,"similar":[{"pmid":32415260,"title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","text":["Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.","Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable.","Cell Mol Immunol","Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing","32415260"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is believed to be a major target to block viral entry. Both SARS-CoV-2 and SARS-CoV share this mechanism. Here we functionally analyzed the key amino acid residues located within receptor binding motif of RBD that may interact with human ACE2 and available neutralizing antibodies. The in vivo experiments showed that immunization with either the SARS-CoV RBD or SARS-CoV-2 RBD was able to induce strong clade-specific neutralizing antibodies in mice; however, the cross-neutralizing activity was much weaker, indicating that there are distinct antigenic features in the RBDs of the two viruses. This finding was confirmed with the available neutralizing monoclonal antibodies against SARS-CoV or SARS-CoV-2. It is worth noting that a newly developed SARS-CoV-2 human antibody, HA001, was able to neutralize SARS-CoV-2, but failed to recognize SARS-CoV. Moreover, the potential epitope residues of HA001 were identified as A475 and F486 in the SARS-CoV-2 RBD, representing new binding sites for neutralizing antibodies. Overall, our study has revealed the presence of different key epitopes between SARS-CoV and SARS-CoV-2, which indicates the necessity to develop new prophylactic vaccine and antibody drugs for specific control of the COVID-19 pandemic although the available agents obtained from the SARS-CoV study are unneglectable."],"journal":"Cell Mol Immunol","authors":["Yi, Chunyan","Sun, Xiaoyu","Ye, Jing","Ding, Longfei","Liu, Meiqin","Yang, Zhuo","Lu, Xiao","Zhang, Yaguang","Ma, Liyang","Gu, Wangpeng","Qu, Aidong","Xu, Jianqing","Shi, Zhengli","Ling, Zhiyang","Sun, Bing"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415260","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41423-020-0458-z","keywords":["sars-cov-2","cross-neutralizing antibody","receptor binding motif","spike protein","substitution mutation"],"locations":["vivo"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666991242711400449,"score":644.51825},{"pmid":32454512,"title":"A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.","text":["A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.","An outbreak of the coronavirus disease 2019 (COVID-19)(1-3), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(4) spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.","Nature","Shi, Rui","Shan, Chao","Duan, Xiaomin","Chen, Zhihai","Liu, Peipei","Song, Jinwen","Song, Tao","Bi, Xiaoshan","Han, Chao","Wu, Lianao","Gao, Ge","Hu, Xue","Zhang, Yanan","Tong, Zhou","Huang, Weijin","Liu, William Jun","Wu, Guizhen","Zhang, Bo","Wang, Lan","Qi, Jianxun","Feng, Hui","Wang, Fu-Sheng","Wang, Qihui","Gao, George Fu","Yuan, Zhiming","Yan, Jinghua","32454512"],"abstract":["An outbreak of the coronavirus disease 2019 (COVID-19)(1-3), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(4) spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation."],"journal":"Nature","authors":["Shi, Rui","Shan, Chao","Duan, Xiaomin","Chen, Zhihai","Liu, Peipei","Song, Jinwen","Song, Tao","Bi, Xiaoshan","Han, Chao","Wu, Lianao","Gao, Ge","Hu, Xue","Zhang, Yanan","Tong, Zhou","Huang, Weijin","Liu, William Jun","Wu, Guizhen","Zhang, Bo","Wang, Lan","Qi, Jianxun","Feng, Hui","Wang, Fu-Sheng","Wang, Qihui","Gao, George Fu","Yuan, Zhiming","Yan, Jinghua"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454512","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41586-020-2381-y","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667983494512377856,"score":622.07104},{"pmid":32454513,"title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection.","text":["Human neutralizing antibodies elicited by SARS-CoV-2 infection.","The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.","Nature","Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi","32454513"],"abstract":["The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions(1-3). SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor(2,4-6). Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions."],"journal":"Nature","authors":["Ju, Bin","Zhang, Qi","Ge, Jiwan","Wang, Ruoke","Sun, Jing","Ge, Xiangyang","Yu, Jiazhen","Shan, Sisi","Zhou, Bing","Song, Shuo","Tang, Xian","Yu, Jinfang","Lan, Jun","Yuan, Jing","Wang, Haiyan","Zhao, Juanjuan","Zhang, Shuye","Wang, Youchun","Shi, Xuanling","Liu, Lei","Zhao, Jincun","Wang, Xinquan","Zhang, Zheng","Zhang, Linqi"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454513","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41586-020-2380-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798493798400,"score":548.7768},{"pmid":32298218,"title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","text":["Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.","A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.","Hum Vaccin Immunother","Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena","32298218"],"abstract":["A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel(R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses."],"journal":"Hum Vaccin Immunother","authors":["Chen, Wen-Hsiang","Hotez, Peter J","Bottazzi, Maria Elena"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298218","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1080/21645515.2020.1740560","keywords":["covid-19","heterologous vaccine","sars","sars-cov-2","coronavirus","receptor-binding domain","subunit vaccine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493250699265,"score":540.64594},{"pmid":32065055,"pmcid":"PMC7048180","title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","text":["Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.","The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.","Emerg Microbes Infect","Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei","32065055"],"abstract":["The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."],"journal":"Emerg Microbes Infect","authors":["Tian, Xiaolong","Li, Cheng","Huang, Ailing","Xia, Shuai","Lu, Sicong","Shi, Zhengli","Lu, Lu","Jiang, Shibo","Yang, Zhenlin","Wu, Yanling","Ying, Tianlei"],"date":"2020-02-18T11:00:00Z","year":2020,"_id":"32065055","source":"PubMed","week":"20208|Feb 17 - Feb 23","doi":"10.1080/22221751.2020.1729069","keywords":["2019-ncov","ace2","rbd","sars-cov","monoclonal antibody"],"link_comment_in":"32132669","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490837925889,"score":540.4755}]}